PIP Search Page

Displaying 521 - 540 of 907

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Compliance outcome	Date Published Sort ascending
MHRA-101232-PIP01-23	palopegteriparatide	Treatment of hypoparathyroidism	Yorvipath Yorvipath	Endocrinology-Gynaecology-Fertility-metabolism	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		30/04/2024
MHRA-101230-PIP01-23	teprotumumab	Treatment of thyroid eye disease	Not available at present TEPEZZA	Ophthamology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101122-PIP01-23	ENFORTUMAB VEDOTIN	Treatment of head and neck epithelial malignant neoplasms	Padcev Padcev Padcev	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101100-PIP01-23	Derivative of a benzoimidazole substituted pyrimidine (PF-07220060)	Treatment of breast malignant neoplasms		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101085-PIP01-23	Humanised IgG1 monoclonal antibody against integrin beta-6 conjugated to monomethyl auristatin E via a valine-citrulline linker	Treatment of non-small cell lung cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101355-PIP01-24	(3S,10S,14S)-1-[4-[[(2S)-4-carboxy-2-[(2S)-4-carboxy-2-(6-[18F] fluoropyridin-3-amido)butanamido]butanamido]methyl]phenyl]-3-[(naphthalen-2-yl)methyl]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid ([18F]PSMA-1007)	Visualisation of prostate specific membrane antigen in prostate cancer	Radelumin	Diagnostic Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-100986-PIP02-23	ENCORAFENIB	Treatment of lung cancer	Braftovi Braftovi Braftovi Braftovi Braftovi Braftovi Braftovi Braftovi Braftovi Braftovi Braftovi Braftovi	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-100985-PIP02-23	BINIMETINIB	Treatment of lung cancer	Mektovi Mektovi Mektovi Mektovi Mektovi Mektovi Mektovi Mektovi Mektovi Mektovi	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101270-PIP01-23	SEMAGLUTIDE	Prevention of cardiovascular events in patients with atherosclerosis	Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy	Endocrinology-Gynaecology-Fertility-metabolism	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101090-PIP01-23	tiragolumab	Treatment of hepatocellular carcinoma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101059-PIP01-23	[(2R)-2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl]-trimethylazanium chloride (R-DOTAP chloride) Palmitoyl-KSS-MHGDTPTLHEYMLDLQPETT (HPV-16 E7 1-20) / Palmitoyl-KSS-YMLDLQPETT (HPV-16 E7 11-20) / Palmitoyl-KSS-GQAEPDRAHYNIVTF (HPV-16 E7 43-57) / Palmitoyl-KSS-KKLLMGTLGIVCPICSQKP(HPV-16 E7 82-98) / Palmitoyl-KSS-LLMGTLGIV (HPV-16 E7 82-90) /Palmitoyl-KSS-ELQTTIHDIILECVYCKQQLL (HPV-16 E6 25-45)	Treatment of human papilloma virus (HPV) type 16 positive malignancies		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-100980-PIP01-23	1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro- 2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop- 2-en-1-one adipate	Treatment of non-small cell lung cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-100969-PIP01-23	V940 (mRNA-4157), Modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens	Treatment of lung cancer	Not available at present	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101287-PIP01-23	SUMATRIPTAN NAPROXEN SODIUM	Treatment of migraine headaches	Suvexx 85 mg/500 mg film-coated tablets FI, DK, HU, NO, SE: Nomigrin EE, LT, LV: Migsun PL: Frimig Duo	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-101003-PIP01-23-M01 (update)	garadacimab	Prevention of hereditary angioedema		Immunology -Rheumatology-Transplantation	PM: decision on the application for modification of an agreed paediatric investigation plan.	Yes	Partial Compliance Check Granted	06/03/2024
MHRA-101034-PIP01-23	Belrestotug GSK4428859A	Treatment of lung cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/01/2024
MHRA-100978-PIP01-23	Genetically detoxified Pertussis Toxin (PTgen) and Pertussis Filamentous Haemagglutinin (FHA)	Prevention of Pertussis disease	Pertagen Pertagen Pertagen Pertagen aPgen	Vaccines	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/01/2024
MHRA-100858-PIP01-23	sabatolimab	Treatment of myelodysplastic syndromes		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/01/2024
MHRA-101030-PIP01-23	Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) (SAR443820)	Treatment of Amyotrophic lateral sclerosis		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/01/2024
MHRA-101053-PIP01-23-M01 (update)	DOLUTEGRAVIR ABACAVIR LAMIVUDINE	Treatment of human immunodeficiency virus (HIV-1) infection	TRIUMEQ TRIUMEQ	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	Yes	Full Compliance Check Granted	30/01/2024

Download XLSX